Figure 4

Antitumor effect of DT18. (A) DT18 was coinjected with B16 tumor cells into mice, and tumor volume was measured (n = 8). (B) Effect of Dt18 on B16 cell proliferation was measured by using MTT assay. (C) Human nasopharyngeal carcinoma was grown in nude mice, and DT18 mixed with Fugene6 was injected intratumorally when the tumor reached about 60–100 mm³. Injections were made twice a week and tumor volumes were measured on alternate days (n = 5). (D) Immunohistochemical staining of the tumor tissues with the VEGFR-1-specific antibody in DT18-, INV-Ctrl- or saline-treated mice.